Published in Med J Aust on November 19, 2012
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis (2013) 2.17
Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis (2013) 1.76
Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust (2010) 1.68
Echinocandin antifungal drugs in fungal infections: a comparison. Drugs (2011) 1.67
Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition. Infect Control Hosp Epidemiol (2008) 1.47
Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics (2009) 1.25
Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol (2007) 1.19
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica (2011) 1.17
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol (2006) 1.09
Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis (2012) 1.09
Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. Support Care Cancer (2008) 1.07
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther (2011) 1.07
Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol (2011) 0.96
Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis (Edinb) (2007) 0.94
Catheter-related bloodstream infections in hematology: time for standardized surveillance? Cancer (2007) 0.93
Pneumonia and lung infections due to emerging and unusual fungal pathogens. Semin Respir Crit Care Med (2011) 0.93
The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol (2015) 0.92
Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. J Antimicrob Chemother (2013) 0.91
Bloodstream infections in haematology: risks and new challenges for prevention. Blood Rev (2008) 0.88
The case for antifungal stewardship. Curr Opin Infect Dis (2012) 0.85
Fluoroquinolone prophylaxis: a word of caution. Leuk Lymphoma (2010) 0.83
Utility of a proposed CSP typing nomenclature for Australian Aspergillus fumigatus isolates: Identification of additional CSP types and suggested modifications. J Microbiol Methods (2009) 0.83
Progressive multifocal leukoencephalopathy complicating Waldenström's macroglobulinaemia. Leuk Lymphoma (2003) 0.83
Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients. Expert Rev Pharmacoecon Outcomes Res (2013) 0.82
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Aust Health Rev (2011) 0.81
Legionella pneumophila mip gene sequencing to investigate a cluster of pneumonia cases. Pathology (2003) 0.81
Molecular epidemiology of invasive aspergillosis: lessons learned from an outbreak investigation in an Australian hematology unit. Infect Control Hosp Epidemiol (2009) 0.80
Fluoroquinolone prophylaxis: worth the cost? Leuk Lymphoma (2013) 0.80
Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation. Curr Infect Dis Rep (2009) 0.80
Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leuk Lymphoma (2011) 0.79
Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients. J Antimicrob Chemother (2012) 0.79
Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. Antimicrob Agents Chemother (2013) 0.79
A different kind of "allogeneic transplant": successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma. Leuk Lymphoma (2014) 0.79
Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: clinical significance of quantitative polymerase chain reaction. Med Mycol (2014) 0.78
Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis (2012) 0.78
Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC). Mycoses (2013) 0.77
Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging (2012) 0.77
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Support Care Cancer (2014) 0.76
Complications of sepsis: the role of risk prediction rules, biomarkers and host genetics. Expert Rev Anti Infect Ther (2012) 0.76
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol (2013) 0.76
Anaerobes: not to be forgotten in neutropenic fever. Leuk Lymphoma (2011) 0.75
More than a feeling: new approach required for assessing immunosuppression. Leuk Lymphoma (2013) 0.75
Outpatient therapy for fever and neutropenia is safe but implementation is the key. J Clin Oncol (2013) 0.75
Staphylococcus aureus meningitis: barriers to treatment. Leuk Lymphoma (2012) 0.75
Emerging opportunistic yeast infections in haematology patients. Leuk Lymphoma (2006) 0.75
External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules. Pediatr Infect Dis J (2017) 0.75
Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leuk Lymphoma (2012) 0.75
Challenges facing infectious diseases physicians today. Editorial comment. Curr Opin Infect Dis (2010) 0.75
Public disclosure of health care-associated infections in Australia: quality improvement or parody? Med J Aust (2012) 0.75
Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leuk Lymphoma (2015) 0.75